中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
18期
72-74
,共3页
慢性肺心病%呼吸衰竭%N端脑钠肽前体
慢性肺心病%呼吸衰竭%N耑腦鈉肽前體
만성폐심병%호흡쇠갈%N단뇌납태전체
Chronic pulmonary heart disease%Respiratory failure%NT-proBNP
目的：研究N端脑钠肽前体（NT-ProBNP）与呼吸衰竭及慢性肺源性心脏病的相关性。方法：筛选和收集2012年1月-2013年12月本科收治的符合单纯呼吸衰竭（A组50例）和呼吸衰竭合并慢性肺心病（B组50例）诊断标准的患者。并选取在本院进行健康体检者（C组）的血样50份，进行血液NT-proBNP水平检测。比较三组的血液NT-proBNP水平，并对A、B两组治疗前后的NT-proBNP水平、血气指标进行比较。记录患者6个月内不良事件发生情况。结果：A、B两组治疗前、后的NT-proBNP水平均显著高于C组，差异均有统计学意义（P<0.05）；B组在治疗前NT-proBNP水平显著高于A组，差异有统计学意义（P<0.05）；A、B两组在治疗后的NT-proBNP水平比较无统计学意义（P>0.05）。经过6~12个月随访，在100例呼吸衰竭患者中，因住院期间发生的病情加重需机械通气、心肺复苏或任何原因的死亡等不良事件共23次，因病情加重需再次住院有37次。发生相关不良事件的患者的NT-proBNP水平为（2849.7±394.7）pg/L显著高于未发生不良事件者的（988.7±93.1）pg/L，差异有统计学意义（P<0.05）。结论：NT-proBNP水平与呼吸衰竭患者是否有肺心病及右心受累程度密切相关，是快速判断右心功能不全严重程度以及疗效判断的良好指标。
目的：研究N耑腦鈉肽前體（NT-ProBNP）與呼吸衰竭及慢性肺源性心髒病的相關性。方法：篩選和收集2012年1月-2013年12月本科收治的符閤單純呼吸衰竭（A組50例）和呼吸衰竭閤併慢性肺心病（B組50例）診斷標準的患者。併選取在本院進行健康體檢者（C組）的血樣50份，進行血液NT-proBNP水平檢測。比較三組的血液NT-proBNP水平，併對A、B兩組治療前後的NT-proBNP水平、血氣指標進行比較。記錄患者6箇月內不良事件髮生情況。結果：A、B兩組治療前、後的NT-proBNP水平均顯著高于C組，差異均有統計學意義（P<0.05）；B組在治療前NT-proBNP水平顯著高于A組，差異有統計學意義（P<0.05）；A、B兩組在治療後的NT-proBNP水平比較無統計學意義（P>0.05）。經過6~12箇月隨訪，在100例呼吸衰竭患者中，因住院期間髮生的病情加重需機械通氣、心肺複囌或任何原因的死亡等不良事件共23次，因病情加重需再次住院有37次。髮生相關不良事件的患者的NT-proBNP水平為（2849.7±394.7）pg/L顯著高于未髮生不良事件者的（988.7±93.1）pg/L，差異有統計學意義（P<0.05）。結論：NT-proBNP水平與呼吸衰竭患者是否有肺心病及右心受纍程度密切相關，是快速判斷右心功能不全嚴重程度以及療效判斷的良好指標。
목적：연구N단뇌납태전체（NT-ProBNP）여호흡쇠갈급만성폐원성심장병적상관성。방법：사선화수집2012년1월-2013년12월본과수치적부합단순호흡쇠갈（A조50례）화호흡쇠갈합병만성폐심병（B조50례）진단표준적환자。병선취재본원진행건강체검자（C조）적혈양50빈，진행혈액NT-proBNP수평검측。비교삼조적혈액NT-proBNP수평，병대A、B량조치료전후적NT-proBNP수평、혈기지표진행비교。기록환자6개월내불량사건발생정황。결과：A、B량조치료전、후적NT-proBNP수평균현저고우C조，차이균유통계학의의（P<0.05）；B조재치료전NT-proBNP수평현저고우A조，차이유통계학의의（P<0.05）；A、B량조재치료후적NT-proBNP수평비교무통계학의의（P>0.05）。경과6~12개월수방，재100례호흡쇠갈환자중，인주원기간발생적병정가중수궤계통기、심폐복소혹임하원인적사망등불량사건공23차，인병정가중수재차주원유37차。발생상관불량사건적환자적NT-proBNP수평위（2849.7±394.7）pg/L현저고우미발생불량사건자적（988.7±93.1）pg/L，차이유통계학의의（P<0.05）。결론：NT-proBNP수평여호흡쇠갈환자시부유폐심병급우심수루정도밀절상관，시쾌속판단우심공능불전엄중정도이급료효판단적량호지표。
To study the correlation of NT-proBNP with respiratory failure and chronic pulmonary heart disease.Method:100 patients who diagnosed with pure respiratory failure(the group A,50 cases)and respiratory failure with chronic pulmonary heart disease(the group B,50 cases)were selected in our hospital from January 2012 to December 2013,and healthy persons(the group C,50 cases)were detected the levels of blood NT-proBNP were selected at the same time. NT-proBNP blood levels of the three groups,and NT-proBNP levels,blood gas analysis before and after treatment were compared between the group A and B. Adverse events were recorded within 6 months.Result:Before and after treatment,the NT-proBNP levels of the group A,B were significantly higher the group C(P<0.05). The NT-proBNP levels of the group B were significantly higher than the group A before treatment(P<0.05),but there were no significant difference between the two groups about NT-proBNP levels after treatment(P>0.05). After 6 to 12 months of follow-up,100 cases of respiratory failure in patients,the disease occurred during hospitalization due to exacerbation requiring mechanical ventilation,cardiopulmonary resuscitation,or death from any cause other adverse events were 23 times exacerbations requiring hospitalization had 37 times again. The NT-proBNP levels of occurred related adverse events was (2849.7±394.7)pg/L,and was significantly higher than the patients with no adverse events of(988.7±93.1)pg/L(P<0.05). Conclusion:NT-proBNP levels in patients with respiratory failure,pulmonary heart disease and whether the degree of right ventricular involvement is closely related,is quick to judge a good indicator of the severity of right ventricular dysfunction and the effect of the judgment.
